Abstract
In distinction to idiopathic Parkinson’s disease (PD), the diagnosis of atypical Parkinson syndromes comprises dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). We set out to write a state-of-the-art guideline as to which investigations and examinations help to differentiate PD vs. atypical Parkinson syndromes in clinical routine.
Similar content being viewed by others
References
Anderson TJ, MacAskill MR (2013) Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol. 9(2):74–85
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496–503
Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C et al (2002) Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 17(6):1255–1264
Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger MG, Geurtsen GJ, Antonini A, Weintraub D, Aarsland D (2016) MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Trans (Vienna) 123(4):431–438
Burrell JR, Hodges JR, Rowe JB (2014) Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord 29(5):684–693. doi:10.1002/mds.25872
Busse K, Heilmann R, Kleinschmidt S, Abu-Mugheisib M, Höppner J, Wunderlich C, Gemende I, Kaulitz L, Wolters A, Benecke R, Walter U (2012) Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson’s disease. J Neurol Neurosurg Psychiatry 83:441–447
Cahn-Weiner DA, Williams K, Grace J, Tremont G, Westervelt H, Stern RA (2003) Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol 16(2):85–92
Caslake R, Moore JN, Gordon JC, Harris CE, Counsell C (2008) Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 79:1202–1207
Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG (2015) Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol 14:855–866
Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I (2005) “Applause sign” helps to discriminate PSP from FTD and PD. Neurology 64(12):2132–2133
Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(14):1375–1376
Fiorenzato E, Weis L, Falup-Pecurariu C, Diaconu S, Siri C, Reali E, Pezzoli G, Bisiacchi P, Antonini A, Biundo R (2016) Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Trans (Vienna) 123(12):1435–1442
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676
Gorges M, Pinkhardt EH, Kassubek J (2014) Alterations of eye movement control in neurodegenerative movement disorders. J Ophthalmol 2014:658243
Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Gelpi E, Giese A, Irwin DJ, Meissner W, Pantelyat A, Rajput A, van Swieten J, Troakes C, Antonini A, Bhatia K, Bordelon Y, Christophe Corvol J, Colosimo C, Dodel RD, Grossman M, Kassubek J, Krismer J, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici G, Rowe JB, Schellenberg G, van Eimeren T, Wenning GK, Boxer A, MD, Golbe LI, Litvan I; for the Movement Disorder Society-endorsed PSP Study Group (2017) Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society Criteria. Movement Disorders (in press)
Huppertz HJ, Möller L, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Respondek G, Stamelou M, Schnitzler A, Pinkhardt EH, Oertel WH, Knake S, Kassubek J, Höglinger GU (2016) Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord 31(10):1506–1517
Iranzo A, Lomeña F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, Pavía J, Gallego J, Seppi K, Högl B, Tolosa E, Poewe W (2010) Santamaria J; Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9(11):1070–1077
Josephs KA, Duffy JR (2008) Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 21(6):688–692
Jost WH (2013) Urological problems in Parkinson’s disease: clinical aspects. J Neural Transm (Vienna). 120:587–591
Jost WH, Augustis S (2015) Severity of orthostatic hypotension in the course of Parkinson’s disease: no correlation with the duration of the disease. Parkinsonism Relat Disord. 21:314–316
Jost WH, Del Tredici K, Landvogt C, Braune S (2010) Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegener Dis. 7:341–347
Kassubek J (2014) Diagnostic procedures during the course of Parkinson´s Disease. Basal Ganglia 4:15–18
Kassubek J, Pinkhardt EH (2011) Neuro-ophthalmological alterations in patients with movement disorders. In: Gálvez-Jiménez N, Tuite P (Eds): Uncommon Causes of Movement Disorders, 1st ed. Cambridge University Press (Cambridge, UK), pp 306–315
Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Østergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK, European MSA (2008) Study Group. Red flags for multiple system atrophy. Mov Disord 23(8):1093–1099
Korczyn AD (2015) Vascular parkinsonism—characteristics, pathogenesis and treatment. Nat Rev Neurol. 11(6):319–326
Respondek G, Stamelou M, Kurz, C, Ferguson LW, Rajput A, Chiu WY, van Swieten JC, Troakes C, al Sarraj S, Gelpi E, Gaig C, Tolosa ET, Oertel WH, Roeber S, Arzberger T, Kretzschmar H, Wagenpfeil S, Höglinger GU (2014) The phenotypic spectrum of progressive supranuclear palsy: a multi-centre study on 100 definite cases. Movement Disorders, 29(14):1758–1766
Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (2016) The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. 113:61–69
Ling H, Massey LA, Lees AJ, Brown P, Day BL (2012) Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson’s disease. Brain. 135(Pt 4):1141–1153
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9
Maass S, Levin J, Höglinger GU (2016) Current treatment of multiple system atrophy. Current Treatment Options in Neurology (Volume 18, 2016) 18(12):51
Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG (2009) Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24:500–508
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ (2005) Yamada M; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLK Consortium. Neurology. 65(12):1863–1872
Meyer PT, Hellwig S (2014) Update on SPECT and PET in parkinsonism—part 1: imaging for differential diagnosis. Curr Opin Neurol 27(4):390–397
Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, Möller F, Schnitzler A, Oertel WH, Knake S, Huppertz HJ, Höglinger GU. Manual MRI morphometry in Parkinsonian syndromes. Mov Disord (In press)
Pinkhardt EH, Kassubek J (2011) Ocular motor abnormalities in Parkinsonian syndromes. Parkinsonism Relat Disord. 17(4):223–230
Pinkhardt EH, Jürgens R, Becker W, Valdarno F, Ludolph AC, Kassubek J (2008) Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson’s syndrome, and idiopathic Parkinson’s disease. J Neurol 255(12):1916–1925
Pinkhardt EH, Kassubek J, Süssmuth S, Ludolph AC, Becker W, Jürgens R (2009) Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinson’s disease. J Neurol 256(9):1438–1446
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601
Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, Lanza P, Barone P, Morgante L, Zappia M, Aguglia U, Gallo O (2008) MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246(1):214–221
Respondek G, Höglinger GU (2016) The phenotypic spectrum of Progressive Supranuclear Palsy. Parkinsonism & related disorders. 22(Suppl 1):S34–S36
Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB (2013) The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84(5):544–551
Rizzo G, Martinelli P, Manners D, Scaglione C, Tonon C, Cortelli P, Malucelli E, Capellari S, Testa C, Parchi P, Montagna P, Barbiroli B, Lodi R (2008) Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson’s disease. Brain. 131:2690–2700
Savica R, Kumar N, Ahlskog JE, Josephs KA, Matsumoto JY, McKeon A (2012) Parkinsonism and dropped head: dystonia, myopathy or both? Parkinsonism Relat Disord 18:30–34
Scherfler C, Göbel G, Müller C, Nocker M, Wenning GK, Schocke M, Poewe W, Seppi K (2016) Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology. 86(13):1242–1249
Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014) The ‘swallow tail’ appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 9:e93814
Seppi K, Poewe W (2010) Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 20(1):29–55
Stamelou M, Höglinger GU (2013) Atypical Parkinsonism: an update. Curr Opin Neurol 26:401–405
Stamelou M, Höglinger GU (2016) A review of treatment options for Progressive Supranuclear Palsy. CNS Drugs 30:629–636
Stamelou M, de Silva R, Arias-Carrion O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU (2010) Rational therapeutic approaches to progressive supranuclear palsy. Brain 133:1578–1590
Stamelou M, Knake S, Oertel WH, Höglinger GU (2011) Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 258:549–558
Stamelou M, Diehl-Schmid J, Hapfelmeier A, Kontaxopoulou D, Stefanis L, Oertel WH, Bhatia KP, Papageorgiou SG, Höglinger GU (2015) The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 21(10):1264–1268
Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22:2386–2393
Videnovic A, Golombek D (2013) Circadian and sleep disorders in Parkinson’s disease. Exp Neurol 243:45–56
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128(Pt 6):1247–1258
Acknowledgements
G.U. Höglinger was funded by the Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The meeting of the authors to discuss this consensus statement was sponsored by AbbVie. G.U. Höglinger has served on the advisory boards for AbbVie, Alzprotect, Asceneuron, Bristol-Myers Squibb, Novartis, Roche, Sellas Life Sciences Group, UCB; has received honoraria for scientific presentations from Abbvie, Roche, Teva, UCB, has received research support from CurePSP, the German Academic Exchange Service (DAAD), German Parkinson’s Disease Foundation (DPG), German PSP Association (PSP Gesellschaft), German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF), International Parkinson’s Fonds (IPF), the Sellas Life Sciences Group; has received institutional support from the German Center for Neurodegenerative Diseases (DZNE). J. Kassubek received consulting fees as an advisory board member and honoraria for scientific presentations as a speaker from UCB-Pharma, Teva Pharmaceuticals, Zambon, Medtronic, Desitin, AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Merz Pharmaceuticals and Hoffmann-La Roche. I. Csoti received financial contributions from Novartis Pharma AG for the organization of CME workshops, as well as honoraria for taking part in an expert meeting and advisory boards. She has received honoraria for presentations from Abbvie, Zambon, Boehringer Ingelheim, TEVA Pharma, Lundbeck, Desitin, Orion Pharma and UCB. H. Herbst has received honoraria for scientific presentations and/or advisory board member from Abbvie, Böhringer, Bayer, UCB. R. Ehret is/was member of an advisory boards for Bial, Desitin, Global Kinetics, Gruenenthal, Mundipharma Germany GmbH & Co, Novartis, Roche, Sanofi, Teva, UCB-Pharma and speaker for Abbvie, Desitin, GE Healthcare, Medtronics, Mundipharma Germany, Novartis, Zambon. I. Wellach has received honoraria for scientific presentations and/or advisory board member AbbVie, Grünenthal, Desitin, UCB, Zambon. Jürgen Winkler has received honoraria for scientific presentations outside of the submitted work from Astrum IT GmbH, Teva GmbH, Ever Pharma GmbH, Desitin Arzneimittel GmbH, Abbvie GmbH & Co. KG, Biogen GmbH, GlaxoSmithKline GmbH & Co. KG. W.H. Jost has received honoraria for scientific presentations and/or advisory board member from Abbvie, Allergan, Bial, Desitin, Ipsen, Merz, UCB, Zambon.
Rights and permissions
About this article
Cite this article
Höglinger, G.U., Kassubek, J., Csoti, I. et al. Differentiation of atypical Parkinson syndromes. J Neural Transm 124, 997–1004 (2017). https://doi.org/10.1007/s00702-017-1700-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-017-1700-4